サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1434700

抗糖尿病薬市場：タイプ別、疾患別、患者別-2024-2030年の世界予測

Antidiabetic Drugs Market by Type (Alpha-Glucosidase Inhibitors, Biguanides, DPP-IV (Dipeptidyl Peptidase) Inhibitors), Disease (Diabetes Mellitus Type 1, Diabetes Mellitus Type 2), Patient - Global Forecast 2024-2030
出版日: | 発行: 360iResearch | ページ情報: 英文 190 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
抗糖尿病薬市場：タイプ別、疾患別、患者別-2024-2030年の世界予測
出版日: 2024年01月15日
発行: 360iResearch
ページ情報: 英文 190 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

抗糖尿病薬市場規模は2023年に469億3,000万米ドルと推計され、2024年には514億2,000万米ドルに達し、CAGR 10.14%で2030年には923億2,000万米ドルに達すると予測されます。

抗糖尿病薬の世界市場

主な市場の統計
基準年[2023］ 469億3,000万米ドル
予測年[2024] 514億2,000万米ドル
予測年 [2030] 923億2,000万米ドル
CAGR（%） 10.14%
抗糖尿病薬 Market-IMG1

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは抗糖尿病薬市場を評価する上で極めて重要です。事業戦略や製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、抗糖尿病薬市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1-市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2-市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3-市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4-競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5-製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1-抗糖尿病薬市場の市場規模および予測は？

2-抗糖尿病薬市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3-抗糖尿病薬市場における技術動向と規制の枠組みは？

4-抗糖尿病薬市場における主要ベンダーの市場シェアは？

5-抗糖尿病薬市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 糖尿病の有病率の上昇と人々の肥満の増加
      • 糖尿病管理の重要性に対する患者とヘルスケア従事者の意識の高まり
      • 糖尿病の啓発と治療をサポートする取り組みとプログラム
    • 抑制要因
      • 抗糖尿病薬に関連する悪影響
    • 機会
      • 新しい抗糖尿病薬の継続的な研究開発
      • 政府と非公開会社が連携して安価な医薬品を供給
    • 課題
      • 抗糖尿病薬の承認に対する厳しい規制要件
  • 市場セグメンテーション分析
  • 市場動向分析
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み

第6章 抗糖尿病薬市場：タイプ別

  • α-グルコシダーゼ阻害剤
  • ビグアニデス
  • DPP-IV（ジペプチジルペプチダーゼ）阻害剤
  • GLP-1（グルカゴン様ペプチド）アゴニスト
  • インスリン
    • 中間型インスリン
    • 長時間作用型アナログ
    • プレミックスインスリン
    • 速効性アナログ
    • 短時間作用型アナログ
  • メグリチニド
  • SGLT-II（ナトリウムグルコース輸送タンパク質）阻害剤
  • スルホニル尿素
  • チアゾリジンジオン

第7章 抗糖尿病薬市場：疾患別

  • 1型糖尿病
  • 2型糖尿病

第8章 抗糖尿病薬市場患者別

  • 成人用
  • 高齢者向け
  • 小児

第9章 南北アメリカの抗糖尿病薬市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第10章 アジア太平洋地域の抗糖尿病薬市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第11章 欧州・中東・アフリカの抗糖尿病薬市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第12章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析：主要企業別
  • 競合シナリオ主要企業別の分析

第13章 競争力のあるポートフォリオ

  • 主要な企業プロファイル
    • Abbott Laboratories
    • Alkem Laboratories Ltd.
    • Aristo Pharmaceuticals Pvt. Ltd.
    • Astellas Pharma Inc.
    • AstraZeneca PLC
    • Biocon Limited
    • Boehringer Ingelheim International GmbH
    • Cadila Pharmaceuticals Limited
    • Cipla Limited
    • Dr. Reddy's Laboratories
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd.
    • GlaxoSmithKline PLC
    • Glenmark Pharmaceuticals Ltd.
    • Halozyme Therapeutics, Inc.
    • Johnson & Johnson Services, Inc.
    • Mankind Pharma Ltd.
    • Merck KGaA
    • Novo Nordisk A/S
    • Oramed Pharmaceuticals Inc.
    • Pfizer Inc.
    • PHC Holdings Corporation
    • Sanofi S.A.
    • Takeda Pharmaceutical Company Limited
    • Teva Pharmaceutical Industries Ltd.
    • Tonghua Dongbao Pharmaceutical Co., Ltd.
  • 主要な製品ポートフォリオ

第14章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. ANTIDIABETIC DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. ANTIDIABETIC DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. ANTIDIABETIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. ANTIDIABETIC DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. ANTIDIABETIC DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. ANTIDIABETIC DRUGS MARKET DYNAMICS
  • FIGURE 7. ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 8. ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2023 VS 2030 (%)
  • FIGURE 10. ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2023 VS 2030 (%)
  • FIGURE 12. ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES ANTIDIABETIC DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES ANTIDIABETIC DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. ANTIDIABETIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 22. ANTIDIABETIC DRUGS MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. ANTIDIABETIC DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. ANTIDIABETIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 6. ANTIDIABETIC DRUGS MARKET SIZE, BY ALPHA-GLUCOSIDASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. ANTIDIABETIC DRUGS MARKET SIZE, BY BIGUANIDES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. ANTIDIABETIC DRUGS MARKET SIZE, BY DPP-IV (DIPEPTIDYL PEPTIDASE) INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. ANTIDIABETIC DRUGS MARKET SIZE, BY GLP-1 (GLUCAGON-LIKE PEPTIDE) AGONISTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 12. ANTIDIABETIC DRUGS MARKET SIZE, BY INTERMEDIATE-ACTING INSULIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. ANTIDIABETIC DRUGS MARKET SIZE, BY LONG-ACTING ANALOG, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. ANTIDIABETIC DRUGS MARKET SIZE, BY PREMIXED INSULIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. ANTIDIABETIC DRUGS MARKET SIZE, BY RAPID-ACTING ANALOG, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. ANTIDIABETIC DRUGS MARKET SIZE, BY SHORT-ACTING ANALOG, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. ANTIDIABETIC DRUGS MARKET SIZE, BY MEGLITINIDES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. ANTIDIABETIC DRUGS MARKET SIZE, BY SGLT-II (SODIUM GLUCOSE TRANSPORT PROTEINS) INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. ANTIDIABETIC DRUGS MARKET SIZE, BY SULPHONYLUREAS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. ANTIDIABETIC DRUGS MARKET SIZE, BY THIAZOLIDINEDIONE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 22. ANTIDIABETIC DRUGS MARKET SIZE, BY DIABETES MELLITUS TYPE 1, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. ANTIDIABETIC DRUGS MARKET SIZE, BY DIABETES MELLITUS TYPE 2, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 25. ANTIDIABETIC DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. ANTIDIABETIC DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. ANTIDIABETIC DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES ANTIDIABETIC DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. AUSTRALIA ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 61. AUSTRALIA ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 62. AUSTRALIA ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. CHINA ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 65. CHINA ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 66. CHINA ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. INDIA ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 69. INDIA ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 70. INDIA ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. INDONESIA ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 73. INDONESIA ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 74. INDONESIA ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. JAPAN ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 77. JAPAN ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 78. JAPAN ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. MALAYSIA ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 81. MALAYSIA ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 82. MALAYSIA ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. PHILIPPINES ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 85. PHILIPPINES ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 86. PHILIPPINES ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SINGAPORE ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 89. SINGAPORE ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 90. SINGAPORE ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. SOUTH KOREA ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 93. SOUTH KOREA ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 94. SOUTH KOREA ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. TAIWAN ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 97. TAIWAN ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 98. TAIWAN ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. THAILAND ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 101. THAILAND ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 102. THAILAND ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. VIETNAM ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 105. VIETNAM ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 106. VIETNAM ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. DENMARK ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 114. DENMARK ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 115. DENMARK ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. EGYPT ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 118. EGYPT ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 119. EGYPT ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. FINLAND ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 122. FINLAND ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 123. FINLAND ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. FRANCE ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 126. FRANCE ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 127. FRANCE ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. GERMANY ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 130. GERMANY ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 131. GERMANY ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. ISRAEL ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 134. ISRAEL ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 135. ISRAEL ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. ITALY ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 138. ITALY ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 139. ITALY ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. NETHERLANDS ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 142. NETHERLANDS ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 143. NETHERLANDS ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. NIGERIA ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 146. NIGERIA ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 147. NIGERIA ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. NORWAY ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 150. NORWAY ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 151. NORWAY ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. POLAND ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 154. POLAND ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 155. POLAND ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. QATAR ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 158. QATAR ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 159. QATAR ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. RUSSIA ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 162. RUSSIA ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 163. RUSSIA ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. SAUDI ARABIA ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 166. SAUDI ARABIA ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 167. SAUDI ARABIA ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 170. SOUTH AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 171. SOUTH AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. SPAIN ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 174. SPAIN ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 175. SPAIN ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. SWEDEN ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 178. SWEDEN ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 179. SWEDEN ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. SWITZERLAND ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 182. SWITZERLAND ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 183. SWITZERLAND ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. TURKEY ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 186. TURKEY ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 187. TURKEY ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED ARAB EMIRATES ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED ARAB EMIRATES ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED ARAB EMIRATES ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED KINGDOM ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 194. UNITED KINGDOM ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 195. UNITED KINGDOM ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 196. ANTIDIABETIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 197. ANTIDIABETIC DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 198. ANTIDIABETIC DRUGS MARKET LICENSE & PRICING
目次
Product Code: MRR-437896AA367B

[190 Pages Report] The Antidiabetic Drugs Market size was estimated at USD 46.93 billion in 2023 and expected to reach USD 51.42 billion in 2024, at a CAGR 10.14% to reach USD 92.32 billion by 2030.

Global Antidiabetic Drugs Market

KEY MARKET STATISTICS
Base Year [2023] USD 46.93 billion
Estimated Year [2024] USD 51.42 billion
Forecast Year [2030] USD 92.32 billion
CAGR (%) 10.14%
Antidiabetic Drugs Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Antidiabetic Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Antidiabetic Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Antidiabetic Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Alkem Laboratories Ltd., Aristo Pharmaceuticals Pvt. Ltd., Astellas Pharma Inc., AstraZeneca PLC, Biocon Limited, Boehringer Ingelheim International GmbH, Cadila Pharmaceuticals Limited, Cipla Limited, Dr. Reddy's Laboratories, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Glenmark Pharmaceuticals Ltd., Halozyme Therapeutics, Inc., Johnson & Johnson Services, Inc., Mankind Pharma Ltd., Merck KGaA, Novo Nordisk A/S, Oramed Pharmaceuticals Inc., Pfizer Inc., PHC Holdings Corporation, Sanofi S.A., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and Tonghua Dongbao Pharmaceutical Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Antidiabetic Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • Alpha-Glucosidase Inhibitors
    • Biguanides
    • DPP-IV (Dipeptidyl Peptidase) Inhibitors
    • GLP-1 (Glucagon-like Peptide) Agonists
    • Insulin
      • Intermediate-Acting Insulin
      • Long-Acting Analog
      • Premixed Insulin
      • Rapid-Acting Analog
      • Short-Acting Analog
    • Meglitinides
    • SGLT-II (Sodium Glucose Transport Proteins) Inhibitors
    • Sulphonylureas
    • Thiazolidinedione
  • Disease
    • Diabetes Mellitus Type 1
    • Diabetes Mellitus Type 2
  • Patient
    • Adult
    • Geriatric
    • Pediatric
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Antidiabetic Drugs Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Antidiabetic Drugs Market?

3. What are the technology trends and regulatory frameworks in the Antidiabetic Drugs Market?

4. What is the market share of the leading vendors in the Antidiabetic Drugs Market?

5. Which modes and strategic moves are suitable for entering the Antidiabetic Drugs Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Antidiabetic Drugs Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of diabetes and increasing obesity among people
      • 5.1.1.2. Growing awareness among patients and healthcare professionals regarding the importance of diabetes management
      • 5.1.1.3. Initiatives and programs supporting diabetes awareness & treatment
    • 5.1.2. Restraints
      • 5.1.2.1. Adverse effects associated with antidiabetic drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing research and development for new antidiabetic drugs
      • 5.1.3.2. Governments and private companies collaborations to supply inexpensive drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory requirements for the approval of antidiabetic drugs
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Antidiabetic Drugs Market, by Type

  • 6.1. Introduction
  • 6.2. Alpha-Glucosidase Inhibitors
  • 6.3. Biguanides
  • 6.4. DPP-IV (Dipeptidyl Peptidase) Inhibitors
  • 6.5. GLP-1 (Glucagon-like Peptide) Agonists
  • 6.6. Insulin
    • 6.7.1. Intermediate-Acting Insulin
    • 6.7.2. Long-Acting Analog
    • 6.7.3. Premixed Insulin
    • 6.7.4. Rapid-Acting Analog
    • 6.7.5. Short-Acting Analog
  • 6.7. Meglitinides
  • 6.8. SGLT-II (Sodium Glucose Transport Proteins) Inhibitors
  • 6.9. Sulphonylureas
  • 6.10. Thiazolidinedione

7. Antidiabetic Drugs Market, by Disease

  • 7.1. Introduction
  • 7.2. Diabetes Mellitus Type 1
  • 7.3. Diabetes Mellitus Type 2

8. Antidiabetic Drugs Market, by Patient

  • 8.1. Introduction
  • 8.2. Adult
  • 8.3. Geriatric
  • 8.4. Pediatric

9. Americas Antidiabetic Drugs Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Antidiabetic Drugs Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Antidiabetic Drugs Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
  • 12.2. Market Share Analysis, By Key Player
  • 12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

  • 13.1. Key Company Profiles
    • 13.1.1. Abbott Laboratories
    • 13.1.2. Alkem Laboratories Ltd.
    • 13.1.3. Aristo Pharmaceuticals Pvt. Ltd.
    • 13.1.4. Astellas Pharma Inc.
    • 13.1.5. AstraZeneca PLC
    • 13.1.6. Biocon Limited
    • 13.1.7. Boehringer Ingelheim International GmbH
    • 13.1.8. Cadila Pharmaceuticals Limited
    • 13.1.9. Cipla Limited
    • 13.1.10. Dr. Reddy's Laboratories
    • 13.1.11. Eli Lilly and Company
    • 13.1.12. F. Hoffmann-La Roche Ltd.
    • 13.1.13. GlaxoSmithKline PLC
    • 13.1.14. Glenmark Pharmaceuticals Ltd.
    • 13.1.15. Halozyme Therapeutics, Inc.
    • 13.1.16. Johnson & Johnson Services, Inc.
    • 13.1.17. Mankind Pharma Ltd.
    • 13.1.18. Merck KGaA
    • 13.1.19. Novo Nordisk A/S
    • 13.1.20. Oramed Pharmaceuticals Inc.
    • 13.1.21. Pfizer Inc.
    • 13.1.22. PHC Holdings Corporation
    • 13.1.23. Sanofi S.A.
    • 13.1.24. Takeda Pharmaceutical Company Limited
    • 13.1.25. Teva Pharmaceutical Industries Ltd.
    • 13.1.26. Tonghua Dongbao Pharmaceutical Co., Ltd.
  • 13.2. Key Product Portfolio

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing